Figure 1.

CSF neurogranin levels in different diagnostic groups. (A) Scatter plots showing CSF neurogranin levels in healthy control, stable MCI (sMCI), progressive MCI (pMCI) and Alzheimer’s disease (AD). Among the healthy control subjects, 32 individuals progressed to MCI or Alzheimer’s disease dementia during follow-up (progressive healthy controls) (B). The data are presented as medians and interquartile ranges. Differences between groups were assessed by linear regression, adjusted for age and sex. *P < 0.05; **P < 0.01; ***P < 0.0001.